EirGenix (TPE:6589) Beneish M-Score: -3.00 (As of Jul. 05, 2026)


TPE:6589 EirGenix Inc TPE:6589
58 GF Score
Price NT$49.70
GF Value NT$92.26
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is EirGenix Beneish M-Score?

EirGenix TPE:6589 +5.97% 58 Beneish M-Score is -3.00 as of Jul. 05, 2026. GuruFocus rates TPE:6589 with a GF Score™ of 58/100 and a GF Value™ of NT$92.26 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 825 Biotechnology companies, EirGenix ranks better than 74.91% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for EirGenix's Beneish M-Score or its related term are showing as below:

TPE:6589' s Beneish M-Score Range Over the Past 10 Years
Min: -3   Med: -2.18   Max: -0.58
Current: -3

During the past 13 years, the highest Beneish M-Score of EirGenix was -0.58. The lowest was -3.00. And the median was -2.18.


EirGenix Beneish M-Score Historical Data

* Premium members only.

The historical data trend for EirGenix's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EirGenix Beneish M-Score Chart

EirGenix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.17 -1.33 -0.58 -2.72 -3.00

EirGenix Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.72 -2.22 -2.71 -2.17 -3.00

TPE:6589 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, EirGenix's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EirGenix Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EirGenix's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where EirGenix's Beneish M-Score falls into.


TPE:6589
58GF Score
EirGenix Inc TPE:6589
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

EirGenix Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of EirGenix for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7845+0.528 * 1.1255+0.404 * 1.5762+0.892 * 0.9962+0.115 * 1.4988
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1243+4.679 * -0.09669-0.327 * 1.6002
=-3.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$417 Mil.
Revenue was 363.622 + 229 + 230.611 + 181.923 = NT$1,005 Mil.
Gross Profit was 125.733 + 32.538 + 18.398 + 17.16 = NT$194 Mil.
Total Current Assets was NT$4,544 Mil.
Total Assets was NT$10,948 Mil.
Property, Plant and Equipment(Net PPE) was NT$5,294 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$246 Mil.
Selling, General, & Admin. Expense(SGA) was NT$335 Mil.
Total Current Liabilities was NT$1,217 Mil.
Long-Term Debt & Capital Lease Obligation was NT$1,384 Mil.
Net Income was -172.382 + -60.313 + -370.763 + -157.094 = NT$-761 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 613.513 + -34.807 + -168.942 + -111.754 = NT$298 Mil.
Total Receivables was NT$534 Mil.
Revenue was 294.641 + 248.223 + 246.403 + 219.693 = NT$1,009 Mil.
Gross Profit was 100.086 + 78.791 + 22.217 + 17.891 = NT$219 Mil.
Total Current Assets was NT$5,952 Mil.
Total Assets was NT$10,876 Mil.
Property, Plant and Equipment(Net PPE) was NT$4,225 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$302 Mil.
Selling, General, & Admin. Expense(SGA) was NT$299 Mil.
Total Current Liabilities was NT$947 Mil.
Long-Term Debt & Capital Lease Obligation was NT$668 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(417.29 / 1005.156) / (533.952 / 1008.96)
=0.415149 / 0.52921
=0.7845

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(218.985 / 1008.96) / (193.829 / 1005.156)
=0.21704 / 0.192835
=1.1255

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4544.207 + 5294.4) / 10948.039) / (1 - (5952.002 + 4225.17) / 10876.416)
=0.101336 / 0.06429
=1.5762

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1005.156 / 1008.96
=0.9962

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(301.573 / (301.573 + 4225.17)) / (246.279 / (246.279 + 5294.4))
=0.06662 / 0.044449
=1.4988

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(334.854 / 1005.156) / (298.97 / 1008.96)
=0.333136 / 0.296315
=1.1243

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1384.146 + 1217.338) / 10948.039) / ((667.766 + 947.37) / 10876.416)
=0.237621 / 0.148499
=1.6002

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-760.552 - 0 - 298.01) / 10948.039
=-0.09669

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

EirGenix has a M-score of -3.00 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.00 mean?
EirGenix (TPE:6589) has a Beneish M-Score of -3.00 as of Jul. 05, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on EirGenix and its competitors. According to the industry distribution chart, EirGenix ranks #207 out of 825 companies in the Biotechnology industry, placing it in the top 25.1%.
Is EirGenix's Beneish M-Score too high?
EirGenix's current Beneish M-Score is -3.00. Based on the distribution chart, EirGenix ranks #207 out of 825 companies in the Biotechnology industry, which is above the industry midpoint. Overall, EirGenix has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EirGenix's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EirGenix ranks #207 out of 825 companies for Beneish M-Score. This puts EirGenix in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on EirGenix and its competitors. EirGenix's current Beneish M-Score is -3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EirGenix stock overvalued right now?
Based on GuruFocus' analysis, EirGenix (TPE:6589) is currently considered Possible Value Trap. The stock's GF Value™ is NT$92.26, compared to a current price of NT$49.70 — trading 46.1% below its estimated fair value. The current Beneish M-Score is -3.00. EirGenix's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For EirGenix (TPE:6589), the current Beneish M-Score is -3.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is EirGenix (TPE:6589) Overvalued in 2026?

Based on GuruFocus' analysis, EirGenix stock appears to be undervalued. The current stock price of NT$49.70 is trading 46.1% below its estimated GF Value™ of NT$92.26. GuruFocus considers EirGenix to be Possible Value Trap.

Key valuation signals for TPE:6589:

  • Beneish M-Score: -3.00
  • GF Value™: NT$92.26 vs. price of NT$49.70 (46.1% below fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the TPE:6589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EirGenix Business Description

Address No. 101, Lane 169, Kangning Street, Xizhi District, New Taipei, TWN, 22180
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST. The revenue is derived from biopharmaceutical contract development and manufacturing services, sales of authorization and cooperative development, and sales of goods. Geographically, it operates in Japan, Taiwan, USA and Canada, Mainland China, Hong Kong, and Macao, and Europe, Others.
58GF Score

Get the complete analysis for TPE:6589

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.70
Price
NT$92.26
GF Value